Leadership & Pay ·
Eikon Therapeutics, Inc. announced the appointment of Ma
EIKNEikon Therapeutics, Inc.
Eikon Therapeutics, Inc. announced the appointment of Ma. Fatima D. Francisco to its Board of Directors as a Class I director, effective June 15, 2026. Ms. Francisco will serve until the 2027 annual meeting of stockholders, serving on the Compensation Committee. Her compensation package includes a $50,000 annual retainer and an option to purchase 85,937 shares of common stock at an exercise price of $8.96 per share. Eikon Therapeutics, Inc. is a biotechnology company focused on developing therapeutic solutions through high-throughput screening technology.